Literature DB >> 19931194

"Personalizing" academic medicine: opportunities and challenges in implementing genomic profiling.

David J Tweardy1, John W Belmont.   

Abstract

BCM faculty members spearheaded the development of a first-generation Personal Genome Profile (Baylor PGP) assay to assist physicians in diagnosing and managing patients in this new era of medicine. The principles that guided the design and implementation of the Baylor PGP were high quality, robustness, low expense, flexibility, practical clinical utility, and the ability to facilitate broad areas of clinical research. The most distinctive feature of the approach taken is an emphasis on extensive screening for rare disease-causing mutations rather than common risk-increasing polymorphisms. Because these variants have large direct effects, the ability to screen for them inexpensively could have a major immediate clinical impact in disease diagnosis, carrier detection, presymptomatic detection of late onset disease, and even prenatal diagnosis. In addition to creating a counseling tool for individual "consumers," this system will fit into the established medical record and be used by physicians involved in direct patient care. This article describes an overall framework for clinical diagnostic array genotyping and the available technologies, as well as highlights the opportunities and challenges for implementation.

Entities:  

Mesh:

Year:  2009        PMID: 19931194      PMCID: PMC2830892          DOI: 10.1016/j.trsl.2009.09.008

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  20 in total

Review 1.  ADME pharmacogenetics: current practices and future outlook.

Authors:  Iris Grossman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-05       Impact factor: 4.481

Review 2.  Common genetic variation and human disease.

Authors:  Nick Orr; Stephen Chanock
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

3.  The complete genome of an individual by massively parallel DNA sequencing.

Authors:  David A Wheeler; Maithreyan Srinivasan; Michael Egholm; Yufeng Shen; Lei Chen; Amy McGuire; Wen He; Yi-Ju Chen; Vinod Makhijani; G Thomas Roth; Xavier Gomes; Karrie Tartaro; Faheem Niazi; Cynthia L Turcotte; Gerard P Irzyk; James R Lupski; Craig Chinault; Xing-zhi Song; Yue Liu; Ye Yuan; Lynne Nazareth; Xiang Qin; Donna M Muzny; Marcel Margulies; George M Weinstock; Richard A Gibbs; Jonathan M Rothberg
Journal:  Nature       Date:  2008-04-17       Impact factor: 49.962

4.  Genetic disorders in children and young adults: a population study.

Authors:  P A Baird; T W Anderson; H B Newcombe; R B Lowry
Journal:  Am J Hum Genet       Date:  1988-05       Impact factor: 11.025

5.  ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs.

Authors:  Denis A Smirnov; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2008-08       Impact factor: 11.025

Review 6.  Genotyping platforms for mass-throughput genotyping with SNPs, including human genome-wide scans.

Authors:  Karen Maresso; Ulrich Broeckel
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

7.  Revealing a subclinical salt-losing phenotype in heterozygous carriers of the novel S562P mutation in the alpha subunit of the epithelial sodium channel.

Authors:  Felix G Riepe; Miguel X P van Bemmelen; Francois Cachat; Hansjörg Plendl; Ivan Gautschi; Nils Krone; Paul-Martin Holterhus; Gerald Theintz; Laurent Schild
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02       Impact factor: 3.478

Review 8.  Warfarin pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

Review 9.  Clinical and pharmacogenetic factors associated with irinotecan toxicity.

Authors:  Dinemarie Kweekel; Henk-Jan Guchelaar; Hans Gelderblom
Journal:  Cancer Treat Rev       Date:  2008-06-16       Impact factor: 12.111

10.  Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study.

Authors:  Ariel Brautbar; Christie M Ballantyne; Kim Lawson; Vijay Nambi; Lloyd Chambless; Aaron R Folsom; James T Willerson; Eric Boerwinkle
Journal:  Circ Cardiovasc Genet       Date:  2009-04-21
View more
  4 in total

1.  Genetics patients' perspectives on clinical genomic testing.

Authors:  Michelle L McGowan; Allison Glinka; Janelle Highland; George Asaad; Richard R Sharp
Journal:  Per Med       Date:  2013-06-01       Impact factor: 2.512

Review 2.  Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer.

Authors:  Jean-Pierre Gillet; Michael M Gottesman
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

Review 3.  Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective.

Authors:  Hugh J S Dawkins; Ruxandra Draghia-Akli; Paul Lasko; Lilian P L Lau; Anneliene H Jonker; Christine M Cutillo; Ana Rath; Kym M Boycott; Gareth Baynam; Hanns Lochmüller; Petra Kaufmann; Yann Le Cam; Virginie Hivert; Christopher P Austin
Journal:  Clin Transl Sci       Date:  2017-10-23       Impact factor: 4.689

4.  SNP-SNP interactions as risk factors for aggressive prostate cancer.

Authors:  Venkatesh Vaidyanathan; Vijay Naidu; Nishi Karunasinghe; Anower Jabed; Radha Pallati; Gareth Marlow; Lynnette R Ferguson
Journal:  F1000Res       Date:  2017-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.